Articles tagged with Tumor Growth
Researchers have identified regional biological signatures in invasive brain tumor margins of high-grade glioma, which could lead to improved diagnosis, prognosis, and treatment. Advanced MRI techniques may help distinguish between the genetic and molecular alterations, providing insights into resistance to treatment.
A Phase 3 clinical trial found that combining testosterone-blocking drugs prevents cancer spread and extends treatment time in patients with relapsed prostate cancer. The approach is more effective than single-drug treatment in delaying cancer progression.
Dr. Mikhail V. Blagosklonny, a renowned oncologist, shares his personal journey with metastatic brain cancer and challenges conventional treatment approaches. He argues that targeted drugs alone cannot cure lung cancer, but preemptive combinations may offer hope.
A new study published in Oncogene highlights the effectiveness of MDX-124, a therapeutic drug targeting annexin-A1, which promotes tumour progression. High annexin-A1 expression levels correlate with poorer overall survival in various cancers.
Researchers identified a new PD-1 immune checkpoint mechanism promoting merkel cell carcinoma growth. MCC cells express PD-1 and its receptor binding accelerates tumor growth via mTOR pathway activation.
A study by the University of Sheffield found that breast cancer cells take advantage of nutrients in the extracellular matrix when faced with nutrient starvation. The cells use an ingestion process called macropinocytosis to consume the matrix, breaking it down into energy-releasing substrates.
Breast cancer cells survive by consuming the extracellular matrix when nutrients are scarce. The process involves macropinocytosis and metabolic conversion of key amino acids to energy-releasing substrates. This mechanism could represent a novel therapeutic target.
A recent study published in Genome Medicine has identified 103 genes that cause inherited diseases when mutated can also increase cancer risk. The research found that individuals with these genes are more likely to develop cancer than those without them.
Researchers have developed nanodrones that target and eliminate cancer cells by recruiting natural killer cells to tumor sites. The study offers a potential solution for intractable types of cancers, with promising results in suppressing tumor growth without causing side effects.
GFH009 inhibits tumor growth and induces apoptosis in various HHM-derived cell lines. The compound's mechanism of action involves rapid 'on-off' inhibition of CDK9, which exerts a proapoptotic effect on cancer cells.
Researchers at UNIST developed a novel one-pot process for growing Bdellovibrio bacteriovorus, a predatory bacterium with potential as 'living antibiotics'. This approach eliminated the need for multiple vessels and reduced growth time by over 50%, enabling large-scale cultivation without compromising efficacy.
Researchers have made significant progress in understanding the enzyme SMYD3's involvement in prostate cancer's progression to a more aggressive stage. The study found that adding methyl groups to the MAP kinase protein is likely SMYD3's role in driving metastasis, and compounds that can inactivate SMYD3 are already available
Researchers discovered a novel therapeutic target BAMBI that suppresses immune cells, reducing the effectiveness of radiation therapy and inducing therapy resistance in cancer patients. BAMBI's expression is associated with improved survival rates, suggesting it as a promising approach to overcome radiation therapy resistance.
Researchers explore the properties of cytostatic persisters in cancer treatment, highlighting their therapeutic potential and challenges. The study suggests that targeting these persisters before resistance emerges can reduce cancer recurrence.
Researchers discuss recent advances in blood-based liquid biopsies for prostate cancer interrogation, highlighting key biomarkers like CTCs, ctDNA, and exosomes. The studies suggest that these approaches can aid in predicting tumor recurrence, improving treatment response, and evaluating prognosis.
Researchers have decoded the factor driving rapid growth of T cell lymphomas, revealing a 'sugar appetite' that triggers processes leading to tumor growth. The discovery provides new hope for treating aggressive cancer types, with existing medications potentially effective against these tumors.
Researchers leverage AI to analyze healthcare data and identify new targets for effective therapies and accelerate drug development in aging research. AI can tailor cancer treatment more precisely to individual patients' unique aging profiles, optimizing treatment outcomes and minimizing risks.
Researchers at West Virginia University are using artificial intelligence to analyze habanero peppers and develop new methods for predicting genetic traits. The goal is to improve crop yields and prevent genetic diseases, with potential applications in human health.
Researchers at Salk Institute discovered how anti-cancer drugs can prevent fibroblast activation, a protective barrier around pancreatic tumors. The therapy reduces tumor growth and slows disease progression in mice and human patients, offering a promising treatment for pancreatic cancer.
Researchers from Japan have discovered a novel targeted molecular therapy using microRNA-451a to suppress the progression of gemcitabine-resistant biliary tract cancers. The study found that miR-451a significantly diminished cell proliferation, induced cell death, and reduced chemoresistance in cancer cells.
Scientists have developed a drug-eluting hydrogel that provides sustained, pH-dependent drug co-delivery and promotes anti-tumor immune responses, reducing tumor cell proliferation and growth. The treatment shows promise in treating hepatocellular carcinoma, with enhanced efficacy compared to traditional methods.
A new study by Tulane University has identified a previously unknown molecular pathway that could halt lung cancer growth. The research found that protein RBM10 can suppress lung cancer by targeting the function of c-Myc, a protein that drives cancer cell growth and proliferation.
A team of researchers from Texas A&M University is developing a low-cost, safe, and controlled cancer treatment using programmable bacteria. The $20 million project aims to create an efficient bacterial therapeutic that can target cancer cells with high precision, reducing side effects and costs.
A new study at the University of Turku discovered that plixorafenib inhibits multiple signaling pathways in cutaneous squamous cell carcinoma, showing promise for treatment. The drug was originally developed for melanoma and lung cancer, but its effectiveness against cSCC is significant.
Scientists at Texas Biomedical Research Institute found a promising cancer therapy also effectively reduces TB growth, even for drug-resistant bacteria. The therapy combines MCL-1 and BCL-2 inhibitors with antibiotics to control TB up to 98%.
Elea Abisamra's STEM writing program at Virginia Tech has been recognized by the journal Cell for its innovative approach to teaching science through storytelling. The program has already helped 95 kids publish books with over 150 tutors as editors, and plans to expand globally.
Researchers found that breast cancer cells rely on vitamin B5 to grow and survive. In a study published in Nature Metabolism, scientists discovered that limiting vitamin B5 intake slowed the growth of breast cancer tumours in mice.
A new study reveals a link between the removal of the FGFR1 protein's extracellular domain and a significant decrease in tumour volume. This finding offers a potential new avenue of treatment for patients with squamous cell carcinoma of the lungs, who have shown limited success with current therapies.
Researchers identified a mechanism that fuels cancer cell growth and developed a new strategy to restrict this process. By restricting glucose in lung cancer cells, they found it caused the cells to lose their specialized features, making them more aggressive.
Researchers created an immunodeficient mouse model of physiological ovarian aging, mirroring female fertility decline with age. The study found decreased oocyte quality, impaired follicle activation and growth, and increased mitochondrial dysfunctions in Old mice.
Researchers have discovered that tumors can hijack and exploit the nervous system's electrical signals to drive their growth and form working connections with healthy cells. This new field of medicine, cancer neuroscience, offers opportunities to target deadly forms of cancer, including brain tumors.
A team of researchers at Kyoto University has found that a deficiency in the enzyme B4GALT3 inhibits tumor growth in mice. The study shows that reduced glycosylation on T cell surfaces correlates with increased CD8+ immune cells infiltrating tumors.
A team of researchers found that fibroblast cells cultured on substrates with varying degrees of stiffness exhibit changes in cell structure, function, and TGF-β activity, which regulates ECM architecture. This study provides insights into how mechanical forces influence wound healing and tissue development.
Researchers at Baylor College of Medicine identified a small molecule named 5D4 that can suppress breast and ovarian cancer growth. 5D4 works by binding to TopBP1 protein in cancer cells, disrupting interactions with multiple pathways that promote cancer growth. Combining 5D4 with PARP inhibitors enhances anti-cancer activity.
A new method for studying cancer cells' behavior on soft and stiff tissue environments has been developed, revealing crucial survival cues for cell growth. The study challenges the long-held assumption that cells prefer stiffer surfaces, opening up new possibilities for research in cancer biology and tissue engineering.
Researchers created a 3D printed tumor model using bioprinting and synthetic chips to better understand complex cancers. The model simulates the surrounding environment, addressing limitations of traditional 2D models.
Researchers discovered that targeting TUG1 can control brain tumor growth in mice, suggesting a potential strategy to combat aggressive brain tumors. By inhibiting TUG1, the therapy significantly suppressed tumor growth and improved survival rates when combined with standard treatment.
Researchers identified YB-1 as an attractive therapeutic target for pleural mesothelioma, a cancer caused by asbestos exposure. Indirect targeting of YB-1 via histone deacetylase inhibitors showed promise in enhancing chemo- and radiotherapy sensitivity.
Researchers discovered a new role for extracellular signal-regulated kinase (ERK) in a pathway activated by interferon-gamma that leads to cancer cell death. Hyperactivation of ERK causes stress in cells, triggering cell death through specific proteins DR5 and NOXA.
Researchers from The University of Queensland and The Alfred hospital in Melbourne have identified gene variants associated with a higher risk of nodular melanoma. The study found that four genes with rare DNA variants were linked to the aggressive subtype, which accounts for most melanoma deaths.
Cancer tumors have been found to hijack the genetic program used by developing nerves, a discovery that could lead to new treatments. The study, published in Frontiers in Genetics, identified key genes controlling nerve growth and development, which are also activated in cancer to facilitate tumor growth and spread.
A new drug called vorasidenib has been shown to significantly slow tumor growth and extend the average time until tumor growth in patients with grade 2 IDH-mutant gliomas. This breakthrough could offer a first early treatment option for these cancer patients, potentially improving their quality of life.
Cancer cells exploit enhancer DNA to accelerate tumor growth, according to researchers at the University of Toronto. The study found that specific proteins regulate this process, suggesting potential treatments through FOXA1 or NFIB suppression.
Researchers at Baylor College of Medicine developed a new compound called d16 that can reduce tumor growth and overcome therapeutic resistance in mutant p53-bearing cancers. The compound, which targets the DNA2 enzyme, shows promise as a potential combination therapy for difficult-to-treat cancers.
A new study found that living donor liver transplant access optimizes the timing of transplant for older, frail cirrhosis patients. Patients with moderate to severe frailty, short stature, and low MELD scores benefited from LDLT, reducing waitlist mortality and improving post-transplant outcomes.
Researchers at Mayo Clinic discovered that senescent macrophages in the lung promote tumor growth by blocking the immune system's response to abnormal cell growth. Eliminating these senescent cells delays tumor formation, suggesting a potential therapeutic target for cancer treatment.
A new MU study found that APRNs recognize the importance of breast cancer survivorship care and can benefit from standardized education. The findings suggest that formalizing education on breast cancer survivorship could lead to improved healthcare for patients, including symptom management, monitoring, and follow-up appointments.
Researchers explore kinase inhibitors as targeted therapies for specific CRC subsets, offering hope for improved treatment options. Key findings suggest that uncovering essential kinases for tumor growth can lead to more effective treatment strategies in metastatic or later-stage CRC patients.
Researchers discovered that fine-tuning mitochondrial energy production reduces melanoma tumor growth and enhances immune response in mice. The study reveals that manipulating mitochondrial electron transport increases expression of immune genes and makes tumor cells more visible to killer T cells.
Researchers at City University of Hong Kong have developed a new class of near-infrared-activated photo-oxidants that can effectively kill cancer cells without requiring oxygen. The discovery offers a promising direction for developing anti-cancer drugs and could overcome existing limitations of photodynamic therapies.
Researchers developed a personalized combination treatment that turned on an immunometabolic switch to effectively control aggressive prostate cancer. The treatment showed complete tumor control and long-lasting survival without side effects in a mouse model of advanced prostate cancer.
Researchers highlight microvascular contributions to white matter injury in Alzheimer's disease, sparking calls for exploration of connections between AD, WM injury and cerebral small vessel disease. The study emphasizes the critical need to define mechanisms and diagnostic features of mixed vascular and AD neuropathological change.
A recent study published in PLOS Biology suggests that chemotherapy injury to surrounding non-cancer cells can awaken dormant breast cancer cells, promoting cancer growth and recurrence. The researchers found that the release of specific cell signaling molecules, G-CSF and IL-6, by injured stromal cells drives this process.
A new editorial paper explores the effectiveness of the third dose booster vaccine against SARS-CoV-2 in immunocompromised individuals. Researchers found that while the vaccine improves vaccine effectiveness across various measures, its benefits are not as significant for patients with cancer.
Researchers discovered that a small subpopulation of AIB1-expressing cells in breast cancer enables invasion and metastasis. The study suggests that these subpopulations play a crucial role in tumor growth and spreading to distant sites.
Salk researchers have identified a new set of molecules that fuel the growth of tumors in pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer. The study found that activating a super-enhancer leads to an increase in protein production, enabling rapid cell growth.
A team of Chinese and UK researchers has identified superoxide dismutase 1 (SOD1) as a potential target for reversing drug resistance in ovarian cancer. By using nanoparticles to deliver siRNA that reduces SOD1 levels, the study showed reduced growth and decreased resistance to cisplatin in female mice.
A new study finds that targeting the ORAI1 calcium channel may provide a promising approach to treating oral cancer. The study reveals that activating this channel causes an influx of calcium into cancer cells, leading to increased pain sensitivity.
Researchers developed a targeted microRNA therapy that slowed cancer tumor growth in a 21-day study. The therapy, which combines a delivery system with modified microRNA-34a, suppressed the activity of genes driving cancer and resistance to other therapies.
Researchers found that antioxidants activate a mechanism forming new blood vessels in tumor cells, which can help them grow and spread. The study suggests that dietary supplements containing antioxidants may accelerate tumour growth and metastasis in cancer patients.